Brand name · Chemotherapy / CD38 Biologic
Darzalex (Daratumumab) J-Code / HCPCS Code
In short
Darzalex is billed under HCPCS J9145 — Injection, daratumumab, 10 mg. One billing unit is 10 mg.
The subcutaneous daratumumab and hyaluronidase product (Darzalex Faspro) has its own code.
Reference
- Code
- J9145 — Injection, daratumumab, 10 mgMed-Code curated
- Billing unit
- 10 mg
- Same code in the directory
- Daratumumab
- Pharmacologic class
- CD38-directed Cytolytic Antibody; EndoglycosidaseFrom the FDA listings below
- Labelers
- Janssen Biotech, Inc.
- J-code category
- Chemotherapy / CD38 Biologic
FDA-listed products
Finished products whose name and route match this directory entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Darzalexdaratumumab | Daratumumab 100 mg/5mL | Injection, Solution, ConcentrateIntravenous | Janssen Biotech, Inc. | 57894-502 |
| Darzalex IVdaratumumab | Daratumumab 100 mg/5mL | Injection, Solution, ConcentrateIntravenous | Janssen Biotech, Inc. | 57894-505 |
Other products with this name
Same name but a different route, formulation or combination — the code above does not apply to these.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant) | Daratumumab 1800 mg/15mL; Hyaluronidase (Human recombinant) 30000 U/15mL | InjectionSubcutaneous | Janssen Biotech, Inc. | 57894-503 |
NDCs billed under J9145
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 2 NDCs to J9145 for Darzalex. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Darzalex | 57894-0505-05 | Janssen Biotech, Inc. | 5 | 10 |
| Darzalex | 57894-0505-20 | Janssen Biotech, Inc. | 20 | 40 |